Navigation Links
Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
Date:6/4/2008

SF1126 is a small-molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms. In addition to inhibiting PI3 kinase, SF1126 inhibits mTOR, DNA-PK, Polo-like 1 kinases, PIM1 and CK2 - all believed to play significant roles in the control of cell survival/proliferation signals and in cancer. SF1126 is the only PI3K inhibitor demonstrated in preclinical studies to cause an oxidative stress mechanism in cancer cells, resulting in decreased proliferation and apoptosis. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is believed that inhibiting this pathway with SF1126 could resensitize the cancer cells to approved anticancer agents and lead to possible synergistic anticancer activity. Clinical combination studies with SF1126 are being planned.

About Semafore Pharmaceuticals

Semafore Pharmaceuticals is a clinical-stage drug discovery and development company focused on small-molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

Semafore is actively seeking partnerships or other strategic alliances to help fulfill the promise of SF1126. For more information visit the company's Web site at http://www.SemaforePharma.com .

Contacts:

Semafore Pharmaceuticals Inc.

Sandi Yurichuk

(650) 576-5769

sandi.yurichuk@semaforepharma.com

Russo Partners LLC

David Schull

(212) 845-4271

david.schull@russopartn
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Pepperl+Fuchs, a ... acquired MACTek Corporation, a leading provider of HART ... strategy to further extend its integrated solutions offerings ...   "We are pleased to add ... portfolio," said Jim Bolin , Pepperl+Fuchs, executive ...
(Date:8/31/2015)... , Aug. 31, 2015  Daktari Diagnostics today announced ... the United States and Canada ... test. The deal, worth up to $8.5 million over the ... the clinical validation and regulatory approval of Daktari,s HCV test. ... a point-of-care instrument that can detect low levels of virus ...
(Date:8/31/2015)... , Aug. 31, 2015  On August 5, ... Oregon denied motions to dismiss ... GALE ) and certain of its directors. The ... a "pump and dump" scheme to artificially inflate Galena,s ... while the stock price was inflated, sold massive amounts ...
Breaking Medicine Technology:Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2
... , , , SAN DIEGO, ... dedicated to developing life-saving medicines specifically designed to enhance ... through targeted oxygen delivery, today announced the initiation of ... efficacy of MP4OX treatment plus standard of care in ...
... Dec. 9 The U.S. Food and Drug Administration ... workshop series--an opportunity for biotechnology companies, pharmaceutical firms, academics ... applications for orphan status designation, under the guidance of ... The first workshop is planned for Feb. 25-26, 2010, ...
Cached Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... years as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical ... general orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... digital marketing communications company announced today that it has officially launched a new ... the new website and brand refresh are more closely aligned with the company’s ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo is pleased to ... Outdoor Sauna. After months of extensive engineering and design of our newest sauna model, ... the elements and is offered at a very attractive price-point. , Before outdoor ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wyoming Medical Center, an acute ... its Clinical Documentation Improvement (CDI) and medical coding needs. Based on a proprietary ... ezCAC is an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance ...
(Date:8/31/2015)... ... August 31, 2015 , ... Castle Dermatology Institute now welcomes San Fernando ... a graduate of the University of California, Los Angeles. He graduated summa cum laude ... of California, Irvine Medical School. As a nationally recognized Regents Scholar, Dr. Ghasri was ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2
... /PRNewswire/ - Neuromed Pharmaceuticals Ltd. announced today that it ... terminate the research collaboration and license agreement for novel ... pain and other disorders, which the companies entered into ... years we have had an excellent and extremely productive ...
... and Communities Critical to Wellness Efforts , , LOS ... the National Childhood Obesity Conference in Los Angeles highlights the ... health crisis caused by childhood obesity. More than 15 ... contributing to skyrocketing type 2 diabetes rates and more than ...
... The Merz Scales(TM) are the most comprehensive rating system to ... than 34 years , , LAS VEGAS, June 11 ... to measure the skin,s aging process, were presented at THE ... of multidisciplinary experts to "establish a universal language of aging," ...
... at August Luncheon , , DENVER, June 11 ... of kidney care services for those diagnosed with chronic kidney ... the Los Angeles Business Journal ,s 2009 "Best Places ... 67 companies chosen for their impact on the region,s economy, ...
... ... Project , ... (PRWEB) June 11, 2009 -- The Critical Access Hospital (CAH) Quality Network of the ... risk, quality and patient safety software and consulting services have joined forces to carry ...
... information, study shows , THURSDAY, June 11 (HealthDay News) -- ... seems to store only the most useful information, researchers have ... students aged 18 to 22, the study findings showed that ... sleep can preserve the most important memories for as long ...
Cached Medicine News:Health News:Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels 2Health News:Kaiser Permanente Calls for Health Policy Support and Community Advocacy to Curb Childhood Obesity 2Health News:Kaiser Permanente Calls for Health Policy Support and Community Advocacy to Curb Childhood Obesity 3Health News:First-Ever Standardized Scales to Measure the Skin's Aging Process Are Presented at THE Aesthetic Show 2Health News:DaVita Named to List of 'Best Places to Work in Los Angeles' by the Los Angeles Business Journal 2Health News:North Dakota Critical Access Hospital Quality Network Moves Forward with Statewide Information Management Project to Enhance Patient Safety in the State 2Health News:North Dakota Critical Access Hospital Quality Network Moves Forward with Statewide Information Management Project to Enhance Patient Safety in the State 3
Introducer Sheath Designed for Vascular Access...
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
Medicine Products: